New Launch2 Feb 2026, 10:15 am
Lupin and TB Alliance Collaborate to Advance Telacebec for Tuberculosis and Other Mycobacterial Diseases Treatment
AI Summary
Global pharma major Lupin Limited has joined forces with TB Alliance, a nonprofit drug developer, to advance the clinical development and commercialization of the investigational drug Telacebec (formerly known as Q203). The collaboration aims to provide advanced treatment options for patients affected by tuberculosis (TB), leprosy, and buruli ulcer. Lupin will contribute its manufacturing scale, global distribution capabilities, regulatory affairs expertise, and supply chain management to ensure global access to Telacebec. TB Alliance will continue to lead the development process.
Key Highlights
- Lupin and TB Alliance collaborate to advance Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer.
- Lupin to provide manufacturing, regulatory affairs, and supply chain expertise to ensure global access to Telacebec.
- TB Alliance to continue leading the development process of Telacebec.
- Telacebec represents scientific innovation with the potential to transform treatment for neglected diseases.
- Collaboration combines deep scientific expertise with global Chemistry, Manufacturing and Controls and access capabilities.